Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2006 (2006), Article ID 15947, 4 pages
http://dx.doi.org/10.1155/SRCM/2006/15947
Clinical Study

A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas

1Gynecological Oncology Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
2Melanoma-Sarcoma Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA

Received 22 July 2005; Revised 26 July 2006; Accepted 17 October 2006

Copyright © 2006 Sibyl E. Anderson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. The role of vinorelbine in specific soft tissue sarcoma subtypes is unclear. We present retrospective single institution experience with single-agent vinorelbine in subjects with metastatic soft tissue malignancies. Methods. Fifty-eight patients were treated with single agent intravenous vinorelbine between April 1997 and December 2004. Doxorubicin had been administered previously to 53 subjects (91%), and the median number of lines of previous chemotherapy was 3 (range 0–7). Results. Patients received a median 6 doses of vinorelbine (range 1–65). The overall response rate was 6% (3 patients: 1 angiosarcoma, 1 epithelioid sarcoma, and 1 embryonal rhabdomyosarcoma). Fourteen patients (26%) experienced a best result of stable disease. Median time to progression was 1.8 months (95% confidence intervals 1.5–2.1 months, Kaplan-Meier estimate). Eight patients experienced grade 3 or 4 toxicity, most commonly febrile neutropenia. Conclusion. Vinorelbine demonstrates limited activity in a heavily pretreated group of soft-tissue sarcoma patients. Prospective investigation may be considered for selected sarcoma subtypes.